FDA Approved Controversial Remdesivir Treatment On Children Infected With CCP Virus

On Apr 25th, the U.S. Food and Drug Administration (FDA) expanded the approval of Remdesivir treatment to CCP virus patients who are aged 28 days and older and weigh at least 3 kilograms. Before this approval, Remdesivir was only approved to treat CCP virus patients above 12 years old and weighing at least 50 kg. As a result of this approval action, the agency also revoked the emergency use authorization for Remdesivir.

Anthony Fauci, Director of the National Institute of Allergy and Infectious Diseases (NIAID), approved and pushed Remdesivir as treatment drug for the CCP virus. However, since its clinical application, many frontline doctors demonstrated Remdesivir was associated with severe side effects like liver and kidney damage, and even death. It was reported that since May 2020, Remdesivir had resulted in at least 30% deaths to everyone who received that drug in hospitals for 5 to 10 days.

In his interview with America Awakening, Doctor Zelenko said from the medical perspective, Remdesivir was a complete failure in his opinion because it killed more patients than the CCP virus did. On Jan 24th, 2022, Dr. Paul Marik, co-founder of the Front Line Covid-19 Critical Care Alliance (FLCCC), revealed in a deposition that the federal government incentivized the hospitals to prescribe medication with severe side effects, namely Remdesivir, instead of cost-effective and safe drugs like ivermectin with a 20% rebate.